Ulrik Nielsen - Merrimack Pharmaceuticals Insider

MACK -- USA Stock  

USD 5.22  0.08  1.51%

Dr. Ulrik B. Nielsen, Ph.D., is Director of Company. He has served as a member of our board of directors since January 2015 and is one of our cofounders. Dr. Nielsen led our research and drug discovery from when he joined us in 2002 to January 2015, including as our Senior Vice President and Chief Scientific Officer from March 2009 until January 2015. Dr. Nielsen has served as President and Chief Executive Officer of Torque Inc., a biotechnology company, since January 2015. Dr. Nielsen also served as Chief Executive Officer of Silver Creek Pharmaceuticals, Inc., a majority owned subsidiary of ours, from July 2010 to March 2014
Age: 43  SVP Since 2015      
617-441-1000  http://www.merrimack.com
Nielsen holds a Ph.D. in molecular biology and an M.S. in biochemistry from the University of Copenhagen.

Management Efficiency

The company has return on total asset (ROA) of (64.63) % which means that it has lost $64.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (19.0) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 3 records

SVP Since

Bob BrownDicerna Pharmaceuticals
David NovackDynavax Technologies Corporatio
Robert CoffmanDynavax Technologies Corporatio

Entity Summary

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 72 people.Merrimack Pharmaceuticals (MACK) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Merrimack Pharmaceuticals Leadership Team

Robert Mulroy, CEO and President Executive Director and Member of Executive Committee
George Demetri, Director
Gary Crocker, Independent Chairman of the Board
Vivian Lee, Director
James Quigley, Director
Birgit Schoeberl, Head of Discovery
Richard Peters, President CEO, Principal Financial Officer, Director
Ulrik Nielsen, Chief Scientific Officer and Sr. VP of Research
John Mendelsohn, Director
John Green, Chief Accounting Officer, Controller
Ellen Forest, Head of Human Resources
Yasir AlWakeel, CFO and Head - Corporate Development
Edward Stewart, Sr. VP of Bus. Devel. and President of Merrimack Healthcare Solutions
Jean Franchi, CFO,Principal Financial Officer, Principal Accounting Officer, Treasurer
William Sullivan, Head of Fin. and Accounting and Treasurer
William Mcclements, Head of Corporate Operations
John Dineen, Director
Russell Ray, Director
Peter Laivins, Head of Devel.
Michael Porter, Independent Director
Geoffrey Grande, IR Contact Officer
Sergio Santillana, Chief Medical Officer

Stock Performance Indicators

Current Sentiment - MACK

Merrimack Pharmaceuticals Investor Sentiment
Most of Macroaxis users are now bullish on Merrimack Pharmaceuticals. What is your trading attitude regarding investing in Merrimack Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.